What to expect next year?, page-181

Hi Patrick.Scott’s preferences for selling other peoples products has been the reason we have not advanced in the past. Nothing has changed. Here we are, we bought Teva with a ship load of useless, out dated generics. Not we’ve spent a fortune on a new wonder pill. It will take 3- 4 years of sales to even break even on what we have spent to get the licences. Even if we exceed expectations with sales, we still have high debt and no new products ready to go.I haven’t heard of any R&D going into new products or clinical trials, which take years to complete. This stock seems to be a one pony show and even Nuvaring should be called old-varying cause by the time we get approval the race is already over. Remember this is a generic version, so the only thing that will make this product pick up any market share is cost. So therefore it will probably be cheaper and the same excuse will be there again as other generics, due to increased competition profits are not there and we’ve decided to write down our costs and move on. This company has no plan and is intent on copying other peoples produces and relying on other peoples R & D.I really wish I had never laid eyes on this stock as it has cost me more than I could ever imagined in believing the constant lies that is MYX.sentiment changed.